News & Updates

Once-only screening with flexible sigmoidoscopy appears to provide prolonged protection against colorectal cancer (CRC), reducing both incidence and mortality rates for up to 2 decades, according to the updated results of the UK Flexible Sigmoidoscopy Screening Trial (UKFSST).

Treatment with dostarlimab combined with carboplatin‒paclitaxel significantly improves overall survival (OS) among patients with primary advanced or recurrent endometrial cancer (EC), with no new safety signals, results of the RUBY trial have shown.

In a post hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial, mirvetuximab soravtansine (MIRV) continues to demonstrate clinically meaningful improvements in survival and objective response rate (ORR) in women with platinum-resistant ovarian cancer (PROC) with high folate receptor-alpha (FRα) expression who necessitated dose modifications.

Treatment with antiplatelet medications and age are some of the factors associated with the occurrence of radiation proctitis in patients with locally advanced cervical cancer treated by chemoradiation, a recent study has shown.

The addition of dostarlimab to a carboplatin-paclitaxel (CP) chemotherapy regimen confers an overall survival (OS) benefit in women with primary advanced or recurrent endometrial cancer (EC), according to the second interim analysis of the ENGOT-EN6/GOG-3031/RUBY trial part 1.

Machine learning models can predict patients with new-onset diabetes who are at greater risk for developing pancreatic cancer, a study has shown.